Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity

Fu,Chunling; Gong,Yanqing; Shi,Xuanxuan; Shi,Hengliang; Wan,Yan; Wu,Qingyun; Xu,Kailin

doi:10.3892/or.2015.4526

Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity

Authors:
- Chunling Fu
- Yanqing Gong
- Xuanxuan Shi
- Hengliang Shi
- Yan Wan
- Qingyun Wu
- Kailin Xu
View Affiliations

Affiliations: Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China
Published online on: December 28, 2015 https://doi.org/10.3892/or.2015.4526
Pages: 1493-1500

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, and mainly originates from an accumulation of abnormal B cells caused by the dysregulation of cell proliferation and apoptosis. The aberration of proliferation-related gene in CLL cells induces cell arrest at G0/G1 phase, or a small section shows rapid cell growth, which further complicates the pathogenesis of CLL. The constitutively photomorphogenic 1 (COP1), as an E3 ubiquitin ligase, is involved in many biological processes in mammalian cells, but its role in chronic lymphocytic leukemia (CLL) progression remains unclear. In the present study, we analyzed the expression of COP1 in peripheral blood mononuclear cells (PBMCs) from 23 CLL patients and 3 healthy donors. The observed upregulated expression of COP1 in CLL patients was positively correlated with CLL clinical stage and ZAP-70 expression, but not del(13q14) and del(17q-). Overexpression of COP1 significantly promoted cell colony formation and proliferation, especially contributing to the accumulation of cells in S-phase by inhibition of FoxO1 and p21. Moreover, overexpression of COP1 accelerated tumorigenicity of HG3 cells and promoted xenograft growth. Therefore, the present study revealed that COP1 plays an important role in CLL cell proliferation and tumorigenicity, and may be a useful indicator of the chronic lymphocytic leukemia processes.

View Figures

View References

1	Malek SN: The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene. 32:2805–2817. 2013. View Article : Google Scholar :
2	Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
3	Bianchi S, Dighiero G and Pritsch O: Selected topics in chronic lymphocytic leukemia pathogenesis. Chronic Lymphocytic Leukemia. InTech; Rijeka: pp. 3–18. 2012
4	Wójtowicz M and Wołowiec D: Dysregulation of apoptosis and proliferation in CLL cells. Chronic Lymphocytic Leukemia. InTech; Rijeka: pp. 37–62. 2012
5	Wang P, Pavletic ZS and Joshi SS: Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation. Leuk Lymphoma. 43:1827–1835. 2002. View Article : Google Scholar
6	Razavi R, Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M and Kreuzer KA: Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res. 17:286–293. 2011. View Article : Google Scholar
7	Halina A, Artur P, Barbara MK, Joanna S and Anna D: Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Folia Histochem Cytobiol. 48:534–541. 2010.
8	Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F and Peschel C: Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 101:278–285. 2003. View Article : Google Scholar
9	Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J and Peschel C: Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 16:327–334. 2002. View Article : Google Scholar : PubMed/NCBI
10	Damle RN, Calissano C and Chiorazzi N: Chronic lymphocytic leukaemia: A disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 23:33–45. 2010. View Article : Google Scholar : PubMed/NCBI
11	Sainz-Perez A, Gary-Gouy H, Gaudin F, Maarof G, Marfaing-Koka A, de Revel T and Dalloul A: IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. J Immunol. 181:6051–6060. 2008. View Article : Google Scholar : PubMed/NCBI
12	Caligaris-Cappio F and Ghia P: Novel insights in chronic lymphocytic leukemia: Are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 26:4497–4503. 2008. View Article : Google Scholar : PubMed/NCBI
13	Soma LA, Craig FE and Swerdlow SH: The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol. 37:152–159. 2006. View Article : Google Scholar : PubMed/NCBI
14	Schwechheimer C and Deng XW: The COP/DET/FUS proteins-regulators of eukaryotic growth and development. Semin Cell Dev Biol. 11:495–503. 2000. View Article : Google Scholar
15	Yi C, Wang H, Wei N and Deng XW: An initial biochemical and cell biological characterization of the mammalian homologue of a central plant developmental switch, COP1. BMC Cell Biol. 3:302002. View Article : Google Scholar : PubMed/NCBI
16	Yi C and Deng XW: COP1 - from plant photomorphogenesis to mammalian tumorigenesis. Trends Cell Biol. 15:618–625. 2005. View Article : Google Scholar : PubMed/NCBI
17	Marine JC: Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer. 12:455–464. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wei W and Kaelin WG Jr: Good COP1 or bad COP1? In vivo veritas. J Clin Invest. 121:1263–1265. 2011. View Article : Google Scholar : PubMed/NCBI
19	Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ and Dixit VM: Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science. 303:1371–1374. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H and Dixit VM: The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 429:86–92. 2004. View Article : Google Scholar : PubMed/NCBI
21	Vitari AC, Leong KG, Newton K, Yee C, O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al: COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 474:403–406. 2011. View Article : Google Scholar : PubMed/NCBI
22	Qi L, Heredia JE, Altarejos JY, Screaton R, Goebel N, Niessen S, Macleod IX, Liew CW, Kulkarni RN, Bain J, et al: TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science. 312:1763–1766. 2006. View Article : Google Scholar : PubMed/NCBI
23	Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J III and Montminy M: Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature. 449:366–369. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kato S, Ding J, Pisck E, Jhala US and Du K: COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem. 283:35464–35473. 2008. View Article : Google Scholar : PubMed/NCBI
25	Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM and French DM: COP1, the negative regulator of p53, is overexpressed in breast and ovarian adeno-carcinomas. Cancer Res. 64:7226–7230. 2004. View Article : Google Scholar : PubMed/NCBI
26	Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, et al: Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res. 70:8264–8269. 2010. View Article : Google Scholar : PubMed/NCBI
27	Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC and Zhou ZW: High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int J Biol Sci. 8:1168–1177. 2012. View Article : Google Scholar : PubMed/NCBI
28	Yoshida A, Kato JY, Nakamae I and Yoneda-Kato N: COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1. Blood. 122:1750–1760. 2013. View Article : Google Scholar : PubMed/NCBI
29	Migliorini D, Bogaerts S, Defever D, Vyas R, Denecker G, Radaelli E, Zwolinska A, Depaepe V, Hochepied T, Skarnes WC, et al: Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest. 121:1329–1343. 2011. View Article : Google Scholar : PubMed/NCBI
30	Rosén A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Björkholm M, Jansson M, Mansouri L, et al: Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology. 1:18–27. 2012. View Article : Google Scholar : PubMed/NCBI
31	Pekarsky Y, Zanesi N and Croce CM: Molecular basis of CLL. Semin Cancer Biol. 20:370–376. 2010. View Article : Google Scholar : PubMed/NCBI
32	Wolowiec D, Wojtowicz M, Ciszak L, Kosmaczewska A, Frydecka I, Potoczek S, Urbaniak-Kujda D, Kapelko-Slowik K and Kuliczkowski K: High intracellular content of cyclin-dependent kinase inhibitor p27^Kip1 in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. Eur J Haematol. 82:260–266. 2009. View Article : Google Scholar : PubMed/NCBI
33	Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, et al: Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (accelerated chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 95:1526–1533. 2010. View Article : Google Scholar
34	Huang H and Tindall DJ: Dynamic FoxO transcription factors. J Cell Sci. 120:2479–2487. 2007. View Article : Google Scholar : PubMed/NCBI